Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(4'-tert-butyl-2',6'-dimethylphenylmethyl)imidazoline
2. Amidrin
3. Balkis
4. Chlorohist-la
5. Decongest
6. Espa-rhin
7. Gelonasal
8. Idasal
9. Idril N
10. Imidin
11. Nasan
12. Nasengel Al
13. Nasengel Ratiopharm
14. Nasenspray Al
15. Nasenspray Ratiopharm
16. Nasentropfen Al
17. Nasentropfen Ratiopharm
18. Novorin
19. Otradrops
20. Otraspray
21. Otriven
22. Otrivin
23. Otrivin Mentol
24. Rapako
25. Schnupfen Endrine
26. Snup
27. Stas
28. Xylometazoline
29. Xylometazoline Monohydrochloride
1. 1218-35-5
2. Xylometazoline Hcl
3. Xylometazoline (hydrochloride)
4. 2-(4-tert-butyl-2,6-dimethylbenzyl)-2-imidazoline Hydrochloride
5. Neo-synephrine Ii
6. Otrivin Hydrochloride
7. Nsc-757378
8. Mls000069695
9. Smr000058526
10. 2-(4-(tert-butyl)-2,6-dimethylbenzyl)-4,5-dihydro-1h-imidazole Hydrochloride
11. Dsstox_cid_25223
12. Dsstox_rid_80760
13. Dsstox_gsid_45223
14. 1h-imidazole, 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-, Hydrochloride (1:1)
15. 2-(4-tert-butyl-2,6-dimethylbenzyl)-4,5-dihydro-1h-imidazole Hydrochloride
16. X5s84033nz
17. Xylometazoline Hydrochloride (usp)
18. 2-(4-tert-butyl-2,6-dimethylbenzyl)-2-imidazoline Monohydrochloride
19. 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazole;hydrochloride
20. Sr-01000000230
21. Ncgc00016101-02
22. Cas-1218-35-5
23. Mfcd00238707
24. Prestwick_574
25. Opera_id_1744
26. Neo-synephrine Ii (tn)
27. Schembl41837
28. Mls001076518
29. Spectrum1500614
30. Chembl1256400
31. Dtxsid3045223
32. Regid_for_cid_5282386
33. Hms1568n07
34. Hms1921k09
35. Pharmakon1600-01500614
36. Xylometazoline Hydrochloride ,(s)
37. Bcp22148
38. Hy-b0475
39. Tox21_110305
40. Tox21_501269
41. Ccg-39900
42. Nsc757378
43. S2576
44. Akos015895456
45. Tox21_110305_1
46. Ac-8301
47. Ks-5144
48. Lp01269
49. Ncgc00016101-10
50. Ncgc00094506-01
51. Ncgc00094506-02
52. Ncgc00094506-03
53. Ncgc00094506-04
54. Ncgc00094506-05
55. Ncgc00261954-01
56. Xylometazoline Hydrochloride [mi]
57. Xylometazoline Hydrochloride [mart.]
58. Xylometazoline Hydrochloride [vandf]
59. Eu-0101269
60. Ft-0603554
61. Sw196748-3
62. X0063
63. Xylometazoline Hydrochloride [usp-rs]
64. Xylometazoline Hydrochloride [who-dd]
65. D00757
66. X 6000
67. Xylometazoline Hydrochloride, Analytical Standard
68. 218x355
69. A804796
70. Xylometazoline Hydrochloride [ep Monograph]
71. J-004686
72. Sr-01000000230-2
73. Sr-01000000230-7
74. Xylometazoline Hydrochloride [usp Monograph]
75. Q27293585
76. Xylometazoline Hydrochloride, British Pharmacopoeia (bp) Reference Standard
77. Xylometazoline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
78. Xylometazoline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
79. Xylometazoline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 280.83 g/mol |
|---|---|
| Molecular Formula | C16H25ClN2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 3 |
| Exact Mass | 280.1706265 g/mol |
| Monoisotopic Mass | 280.1706265 g/mol |
| Topological Polar Surface Area | 24.4 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 302 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Nasal Decongestants
Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Thickeners and Stabilizers
Topical
Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
25
PharmaCompass offers a list of Xylometazoline Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Xylometazoline Hydrochloride manufacturer or Xylometazoline Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Xylometazoline Hydrochloride manufacturer or Xylometazoline Hydrochloride supplier.
PharmaCompass also assists you with knowing the Xylometazoline Hydrochloride API Price utilized in the formulation of products. Xylometazoline Hydrochloride API Price is not always fixed or binding as the Xylometazoline Hydrochloride Price is obtained through a variety of data sources. The Xylometazoline Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A NasenGel ratiopharm manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NasenGel ratiopharm, including repackagers and relabelers. The FDA regulates NasenGel ratiopharm manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NasenGel ratiopharm API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of NasenGel ratiopharm manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A NasenGel ratiopharm supplier is an individual or a company that provides NasenGel ratiopharm active pharmaceutical ingredient (API) or NasenGel ratiopharm finished formulations upon request. The NasenGel ratiopharm suppliers may include NasenGel ratiopharm API manufacturers, exporters, distributors and traders.
click here to find a list of NasenGel ratiopharm suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A NasenGel ratiopharm DMF (Drug Master File) is a document detailing the whole manufacturing process of NasenGel ratiopharm active pharmaceutical ingredient (API) in detail. Different forms of NasenGel ratiopharm DMFs exist exist since differing nations have different regulations, such as NasenGel ratiopharm USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A NasenGel ratiopharm DMF submitted to regulatory agencies in the US is known as a USDMF. NasenGel ratiopharm USDMF includes data on NasenGel ratiopharm's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The NasenGel ratiopharm USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of NasenGel ratiopharm suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a NasenGel ratiopharm Drug Master File in Korea (NasenGel ratiopharm KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of NasenGel ratiopharm. The MFDS reviews the NasenGel ratiopharm KDMF as part of the drug registration process and uses the information provided in the NasenGel ratiopharm KDMF to evaluate the safety and efficacy of the drug.
After submitting a NasenGel ratiopharm KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their NasenGel ratiopharm API can apply through the Korea Drug Master File (KDMF).
click here to find a list of NasenGel ratiopharm suppliers with KDMF on PharmaCompass.
A NasenGel ratiopharm CEP of the European Pharmacopoeia monograph is often referred to as a NasenGel ratiopharm Certificate of Suitability (COS). The purpose of a NasenGel ratiopharm CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of NasenGel ratiopharm EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of NasenGel ratiopharm to their clients by showing that a NasenGel ratiopharm CEP has been issued for it. The manufacturer submits a NasenGel ratiopharm CEP (COS) as part of the market authorization procedure, and it takes on the role of a NasenGel ratiopharm CEP holder for the record. Additionally, the data presented in the NasenGel ratiopharm CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the NasenGel ratiopharm DMF.
A NasenGel ratiopharm CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. NasenGel ratiopharm CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of NasenGel ratiopharm suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing NasenGel ratiopharm as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for NasenGel ratiopharm API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture NasenGel ratiopharm as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain NasenGel ratiopharm and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a NasenGel ratiopharm NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of NasenGel ratiopharm suppliers with NDC on PharmaCompass.
NasenGel ratiopharm Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NasenGel ratiopharm GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right NasenGel ratiopharm GMP manufacturer or NasenGel ratiopharm GMP API supplier for your needs.
A NasenGel ratiopharm CoA (Certificate of Analysis) is a formal document that attests to NasenGel ratiopharm's compliance with NasenGel ratiopharm specifications and serves as a tool for batch-level quality control.
NasenGel ratiopharm CoA mostly includes findings from lab analyses of a specific batch. For each NasenGel ratiopharm CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NasenGel ratiopharm may be tested according to a variety of international standards, such as European Pharmacopoeia (NasenGel ratiopharm EP), NasenGel ratiopharm JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NasenGel ratiopharm USP).
